5 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow PNU-100480: new trials by email Literature Review of PNU-100480 trials Research Report on PNU-100480
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 315 | 2025-03-11 | 2026-10-19 |
| A Pan-TB Regimen Targeting Host and Microbe Sutezolid, N-acetyl cysteine, Pretomanid - Tuberculosis | Phase 2 / Phase 3 | Active not recruiting | The Aurum Institute NPC | 352 | 2023-07-28 | 2025-05-28 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
| PanACEA Sutezolid Dose-finding and Combination Evaluation Sutezolid, Bedaquiline, Delamanid, Moxifloxacin, Midazolam oral solution - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Completed | Michael Hoelscher | 75 | 2021-05-06 | 2023-05-01 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Sutezolid, Placebo - Tuberculosis, Tuberculosis, Pulmonary | Phase 1 | Completed | Global Alliance for TB Drug Development | 32 | 2017-09-26 | 2018-02-08 |
| PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay PNU-100480, RHZE - Tuberculosis | Phase 2 | Completed | Sequella, Inc. | 59 | 2011-08-01 | 2016-01-14 |
| Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers PNU-100480, Placebo, Linezolid - Tuberculosis | Phase 1 | Completed | Sequella, Inc. | 59 | 2009-10-01 | 2013-08-28 |
| Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults PNU-100480, Placebo - Tuberculosis | Phase 1 | Completed | Sequella, Inc. | 19 | 2009-04-01 | 2013-08-27 |
Tuberculosis (6) · Tuberculosis, Pulmonary (4) · Gram-Positive Bacterial Infections (1) · Tuberculosis, Multidrug-Resistant (1)
Sequella, Inc. (3) · Gates Medical Research Institute (1) · Global Alliance for TB Drug Development (1) · Michael Hoelscher (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · The Aurum Institute NPC (1)
South Africa (5) · United States (3) · Philippines (2) · Tanzania (2) · Botswana (1) · Brazil (1) · Haiti (1) · India (1) · Kenya (1) · Malawi (1) · Mexico (1) · Mozambique (1) · Peru (1) · Thailand (1) · Uganda (1)
Lisa Beth Ferstenberg, M.D. (3) · Kelly Dooley, MD, PhD (1) · Michael Hoelscher, Prof. (1) · Paul Bruinenberg, MD (1) · Professor Robert Wallis, MD (1) · Radojka Savic, PharmD, PhD (1)
PMID 20629533, PMID 24732289, PMID 40195983, PMID 40645196, PMID 40817073, PMID 41749341